| Market Capitalization (Millions $) |
3,904 |
| Shares
Outstanding (Millions) |
164 |
| Employees |
1,114 |
| Revenues (TTM) (Millions $) |
336 |
| Net Income (TTM) (Millions $) |
15 |
| Cash Flow (TTM) (Millions $) |
53 |
| Capital Exp. (TTM) (Millions $) |
13 |
Certara Inc
We expedite medicines to patients by transforming traditional drug research and development using biosimulation software, technology, and services.
Biosimulation is a sophisticated technique that allows virtual trials to be conducted using virtual patients in order to better understand how medications respond in various persons. Throughout drug research and development, biopharmaceutical firms utilize our patented biosimulation software to guide important decisions that not only save substantial time and money but also increase drug safety and efficacy, benefitting millions of lives each year.
We build our biosimulation technology on first principles of biology, chemistry, and pharmacology with proprietary mathematical algorithms that model how medicines and diseases behave in the body. For over two decades, we have honed and validated our biosimulation technology with an abundance of data from scientific literature, lab research, and preclinical and clinical studies. In turn, our customers use biosimulation to conduct virtual trials to answer critical questions, such as: What will be the human response to a drug based on preclinical data? How will other drugs interfere with this new drug? What is a safe and efficacious dose for children, the elderly, or patients with pre-existing conditions? Virtual trials may be used to optimize dosing on populations that are otherwise difficult to study for ethical or logistical reasons, such as infants, pregnant women, the elderly, and cancer patients.
We believe that biosimulation continues to grow in adoption, driven by increasing global regulatory support and advancements in technology. We believe we are well-positioned to capture the significant market opportunity ahead of us. Our growth strategy is to build out the depth and breadth of our scalable, end-to-end biopharmaceutical platform to advance all stages of the continuum, from discovery and development to regulatory submission and market access. We continue to innovate and introduce new functionality and uses of biosimulation and technology-driven solutions. We increasingly integrate the science and data we obtain across this end-to-end platform to inform critical decisions. We further reduce the cost and time of human trials to materially accelerate the speed of development and availability of therapies to patients worldwide. As exciting, new research areas arise, we attract and hire specialized talent and acquire businesses to expand our offerings to address these market opportunities.
With continued innovation in and adoption of our biosimulation software, technology and services, we believe more biopharmaceutical companies worldwide will leverage more of our end-to-end platform to reduce cost, accelerate speed to market, and ensure safety and efficacy of medicines for all patients.
Biosimulation: Biosimulation is the mathematical modeling of biological processes and systems to simulate how a drug affects the body, how the body affects the drug, how potential doses will affect different patient groups, and how patients will respond under various clinical scenarios. Biosimulation informs every stage of the drug discovery and development process and brings value through:
Identifying potential winners and losers at an earlier stage and allowing programs to “fail faster;”
Streamlining preclinical and clinical studies or eliminating certain ones altogether;
Optimizing dosing for different populations for enhanced safety and efficacy; and
Increasing probability of success and return on R&D, amongst others.
Regulatory Science: Regulatory science is the development and application of scientific methods, tools, and approaches to support regulatory and other policy objectives. Expert management of these processes is critical to drugs receiving regulatory approval and ultimately reaching patients and generating sales. Providers of regulatory technology and expertise drive significant value for biopharmaceutical companies through:
Utilizing best-in-class technology to reduce time-intensive regulatory writing activities and the need for regulatory writing staff;
Managing submission timelines and other requirements of global regulatory agencies;
Generating clear, accurate applications and submissions; and
Developing comprehensive global regulatory strategies, amongst others.
Market Access: To achieve commercial access, sponsors must assess, optimize and persuasively communicate the value of a new therapy, both therapeutic and economic, that stakeholders such as payors and health care providers will accept and act on. Market access services, including real-world evidence and health economics outcomes research, generate value by:
Creating cost and comparative effectiveness models to support pricing and payor reimbursement;
Analyzing payor needs and using economic models to develop contracting strategies that optimize value; and
Collecting and analyzing real-world data for use in market and payor communications, amongst others.
We believe that our end-to-end platform is well-positioned to continue benefiting from market trends. In addition to continued growth in our core markets, we expect to capture a broader share of overall biopharmaceutical R&D spend as we continue to innovate and add new solutions to our end-to-end platform.
Our Competitive Strengths
We compete by offering a broad and deep combination of industry-standard biosimulation software and technology-driven services across all stages of the continuum, from discovery and development to regulatory approval and market access. We have cultivated the following competitive strengths for more than two decades:
Our Proprietary, Scalable Biosimulation Software
Our proprietary, scalable biosimulation software, built on first principles integrates biosimulation models, scientific knowledge, and data, which we believe would require years of effort, immense resources, and scarce expertise to duplicate. Our versatile biosimulation software is deployed to public and private cloud networks, on-premises, and data centers. Scientists can run multiple simulation projects on a cloud compute platform or internal clusters. We protect our proprietary technology through intellectual property rights, including copyrights, patents, trade secrets, know-how, and trademarks.
Company Address: 100 Overlook Center Princeton 8540 NJ
Company Phone Number: 716-7900 Stock Exchange / Ticker: NASDAQ CERT
| CERT is expected to report next financial results on May 04, 2023. |
|
|
0.13%